title: Assessment of pharmacotherapy for negative symptoms of schizophrenia.
abstract: Negative symptoms in schizophrenia include diminished ability to communicate, motivate, and socialize as potentially debilitating aspects of the illness that are associated with long-term impairment. Despite such burden, the domain has been underrepresented in drug development and treatment research. In this article, we review research regarding pharmacotherapy for negative symptoms, with a focus on studies published during the past 2 years. Clearly positive studies were limited to N-methyl-D-aspartate agonists, while antipsychotics and antidepressants did not show substantial benefit, and cognitive enhancers have yielded mixed results. Proof-of-concept studies of other agents such as minocycline and omega fatty acids yielded promising, albeit preliminary findings that warrant replication. Study outcomes and designs are discussed along with implications for future research.
authors.affiliation: Schizophrenia Research Center, Department of Psychiatry, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, 19104, USA. elizabgh@upenn.edu
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Hanson
authors.forename: Kristin
authors.initials: K
authors.lastname: Healey
authors.forename: Daniel
authors.initials: D
authors.lastname: Wolf
authors.forename: Christian
authors.initials: C
authors.lastname: Kohler
mesh_terms: D000928:Antidepressive Agents / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D018690:Excitatory Amino Acid Agonists / Q000627:therapeutic use*; D006801:Humans; D016194:Receptors, N-Methyl-D-Aspartate / Q000819:agonists*; D012559:Schizophrenia / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D018690:Excitatory Amino Acid Agonists; D016194:Receptors, N-Methyl-D-Aspartate
references.citation: Neuropsychopharmacology. 2000 Oct;23(4):351-64
references.pmid: 10989262
references.citation: Psychiatry Res. 1989 Nov;30(2):119-23
references.pmid: 2616682
references.citation: Schizophr Res. 2007 Jul;93(1-3):109-16
references.pmid: 17383857
references.citation: J Clin Psychiatry. 2009 Apr;70(4):518-25
references.pmid: 19358788
references.citation: J Clin Psychiatry. 2007 Apr;68(4):604-10
references.pmid: 17474817
references.citation: Br J Psychiatry. 1987 Aug;151:145-51
references.pmid: 3690102
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2008 Dec 12;32(8):1810-5
references.pmid: 18727948
references.citation: Arch Gen Psychiatry. 2002 Oct;59(10):921-8
references.pmid: 12365879
references.citation: Neuroimage. 2006 Jan 15;29(2):409-16
references.pmid: 16139525
references.citation: Am J Psychiatry. 2005 Mar;162(3):495-506
references.pmid: 15741466
references.citation: Psychiatry Res. 2010 Feb 28;175(3):271-3
references.pmid: 20045196
references.citation: Psychopharmacol Bull. 1989;25(2):159-63
references.pmid: 2602512
references.citation: J Clin Psychopharmacol. 2009 Jun;29(3):267-71
references.pmid: 19440081
references.citation: J Clin Psychiatry. 2009 Dec;70(12):1674-80
references.pmid: 19689921
references.citation: Cochrane Database Syst Rev. 2006 Jul 19;(3):CD001257
references.pmid: 16855961
references.citation: Eur J Pharmacol. 1994 May 12;257(1-2):7-12
references.pmid: 8082709
references.citation: Isr J Psychiatry Relat Sci. 2009;46(3):213-20
references.pmid: 20039523
references.citation: J Clin Psychiatry. 2009 Oct;70(10):1416-23
references.pmid: 19906345
references.citation: J Clin Psychiatry. 2010 Feb;71(2):138-49
references.pmid: 19895780
references.citation: J Clin Psychiatry. 2006 Dec;67(12):1954-67
references.pmid: 17194275
references.citation: Int J Neuropsychopharmacol. 2010 May;13(4):451-60
references.pmid: 19887019
references.citation: Int Clin Psychopharmacol. 2001 Mar;16(2):87-92
references.pmid: 11236073
references.citation: Schizophr Res. 2009 Mar;108(1-3):245-51
references.pmid: 19144501
references.citation: Arch Gen Psychiatry. 2010 Feb;67(2):146-54
references.pmid: 20124114
references.citation: Hum Psychopharmacol. 2009 Apr;24(3):233-8
references.pmid: 19330802
references.citation: Schizophr Res. 2008 Dec;106(2-3):320-7
references.pmid: 18799288
references.citation: Schizophr Bull. 1987;13(2):261-76
references.pmid: 3616518
references.citation: Biol Psychiatry. 1995 Jul 1;38(1):22-33
references.pmid: 7548469
references.citation: Am J Psychiatry. 2006 May;163(5):790-9
references.pmid: 16648318
references.citation: Arch Gen Psychiatry. 2007 Dec;64(12):1356-66
references.pmid: 18056543
references.citation: CNS Drugs. 2009 Sep;23(9):781-92
references.pmid: 19689168
references.citation: Neuropsychopharmacology. 2009 Jul;34(8):1885-903
references.pmid: 19339966
references.citation: J Clin Psychiatry. 2009 Jun;70(6):801-9
references.pmid: 19573479
references.citation: Schizophr Res. 2010 Feb;116(2-3):101-6
references.pmid: 19959338
references.citation: Psychoneuroendocrinology. 2010 Sep;35(8):1142-7
references.pmid: 20171784
references.citation: J Clin Psychopharmacol. 2008 Apr;28(2 Suppl 1):S4-11
references.pmid: 18334911
references.citation: Schizophr Res. 2009 Feb;107(2-3):332-3
references.pmid: 18995989
references.citation: Neuropsychopharmacology. 2004 Jul;29(7):1363-73
references.pmid: 15085092
references.citation: J Clin Psychiatry. 2009 Apr;70(4):562-71
references.pmid: 19192468
references.citation: Clin Neuropharmacol. 2009 Mar-Apr;32(2):69-74
references.pmid: 18978489
references.citation: Schizophr Res. 2007 Sep;95(1-3):158-68
references.pmid: 17628435
references.citation: Neuropsychopharmacology. 2009 Apr;34(5):1322-9
references.pmid: 19005465
references.citation: Arch Gen Psychiatry. 1994 Mar;51(3):199-214
references.pmid: 8122957
references.citation: Schizophr Bull. 2005 Jan;31(1):5-19
references.pmid: 15888422
references.citation: Hum Psychopharmacol. 2009 Aug;24(6):437-46
references.pmid: 19637398
references.citation: Int Clin Psychopharmacol. 2004 Mar;19(2):71-6
references.pmid: 15076014